Drug intelligence / Profile preview

Dianeal PD1

Development stage
Unknown
Lead developer
Takeda
Modality
Small Molecules
Administration
Intraperitoneal
01

Overview

Dianeal PD1 is a sterile, non-pyrogenic peritoneal dialysis solution developed and manufactured by Baxter. It is primarily indicated for the treatment of patients with chronic renal failure or acute kidney injury who require peritoneal dialysis. The solution functions by utilizing the patient's peritoneum as a semi-permeable membrane; metabolic waste products and excess fluid are removed from the blood into the dialysis solution through the processes of diffusion and osmosis. Dianeal PD1 is specifically formulated with a dextrose (glucose) concentration to provide the necessary osmotic gradient for ultrafiltration and an electrolyte profile that typically includes a lower calcium concentration (1.5 mEq/L) compared to standard solutions. This low-calcium formulation is designed to assist in the management of mineral and bone disorders, such as hypercalcemia, which are common in renal patients. It is administered intraperitoneally via a catheter and is available in various dextrose strengths to tailor fluid removal to the patient's clinical needs.

Brand names
Dianeal PD1
Other names
Dianeal PD-1Peritoneal Dialysis Solution

Beyond the preview

Go deeper on Dianeal PD1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dianeal PD1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call